Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

Tomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Hiroki Nishikawa; Kazunari Tanaka; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Yuichi Koshiyama; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Takashi Nishimura; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Hideyuki Tamai; Takanori Matsuura; Shohei Komatsu; Yoshihide Ueda; Yoshiko Nakamura; Osamu Yoshida; Shinichiro Nakamura; Hirayuki Enomoto; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo

doi:10.1111/hepr.14224

Related publications

Article2025

Clinical Impact of Serum <scp>CRP</scp> Levels on Advanced <scp>HCC</scp> Treated With Durvalumab and Tremelimumab: A Multicentre Study

Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Kosuke Matsui, Atsushi Naganuma, Hironori Tanaka, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Hironori Ochi, Michitaka Imai, Shinichiro Nakamura, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Article2022

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Jaekyung Cheon, Naoshi Nishida, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein,

Article2025

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake,

Article2023

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Masatoshi Kudo, Richard S. Finn, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel, Shukui Qin

Article2022

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

Samuel Hidalgo-Ríos, Jaime Carrillo, David S. Moura, Silvia Stacchiotti, Antonio López–Pousa, Andrés Redondo, Antoîne Italiano, Antonio Gutiérrez, Giovanni Grignani, Nadia Hindi, José Antonio López‐Guerrero, Xavier García del Muro, Javier Martínez‐Trufero, Emanuela Palmerini, Ana García, Daniel Bernabéu, Axel Le Cesne, Paolo G. Casali, Jean Yves Blay, Josefina Cruz Jurado,